Biotech and Pharmaceutical Stocks, Recent Clinical Trial Results
Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
- MHRA Approves XEVUDY (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19on December 7, 2021 at 7:12 pm
MIAMI, Dec. 7, 2021. Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents...
- Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndromeon December 6, 2021 at 11:12 pm
Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement (CGI-I)...
- Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infectionon December 6, 2021 at 10:12 pm
KENILWORTH, N.J.-- December 06, 2021 -- Merck, known as MSD outside the United States and Canada, today announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 clinical studies evaluating...
- Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responseson December 6, 2021 at 7:12 pm
NEW BRUNSWICK, N.J., Dec. 5, 2021. Johnson & Johnson (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D.,...
- Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 Minuteson December 6, 2021 at 3:12 am
NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from the second pivotal clinical trial (NCT04571060) evaluating the safety and efficacy of its...
- Lilly's Bamlanivimab with Etesevimab Authorized as the First and Only Neutralizing Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12on December 3, 2021 at 9:12 pm
INDIANAPOLIS, Dec. 3, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from...
- I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumorson December 3, 2021 at 6:12 pm
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021. I-Mab (the "Company"), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been...
- ViaCyte's Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studieson December 2, 2021 at 6:12 pm
SAN DIEGO, Dec. 2, 2021. ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announced publication of promising preliminary results of...
- Novavax Statement on Omicron Variant Responseon December 2, 2021 at 12:12 am
December 2, 2021 -- Novavax is rapidly responding to the emergence of the latest potential threat of the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC). The company is executing a two-pronged variant strategy. First, Novavax is...
- Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Varianton December 2, 2021 at 12:12 am
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron Data to be confirmed by further in vitro pseudo-virus...
- Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDDon December 1, 2021 at 10:12 pm
CAMBRIDGE, Mass. – December 1, 2021 – Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as...
- Insightec Announces FDA Clearance For Exablate Prostate To Treat Prostate Tissueon December 1, 2021 at 8:12 pm
HAIFA, Israel and MIAMI, Fla., Dec. 1, 2021. Insightec, a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy, announced today that the Exablate Prostate system received FDA...
- Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Programon November 30, 2021 at 7:11 pm
REHOVOT, Israel, Nov. 30, 2021. Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today positive results from pre-clinical...
- Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adultson November 30, 2021 at 4:12 am
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE) November 30, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided the following statement at the conclusion of the U.S. Food and...
- Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Varianton November 29, 2021 at 11:11 pm
November 29, 2021 -- Since the emergence of the COVID-19 pandemic, Johnson & Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the...
- Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agencyon November 29, 2021 at 10:11 pm
PRINCETON, N.J.--(BUSINESS WIRE) November 29, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated...
- Novel Herbal Drug by Xantho Biotechnology Seeks To Be New First-Line Atopic dermatitis Treatmenton November 29, 2021 at 7:11 pm
TAIPEI, Nov. 29, 2021. Botanical drug company Xantho Biotechnology has announced that its atopic dermatitis (AD) treatment, GM-XANTHO, has advanced to phase II of clinical trials. This comes after years of rigorous pre-clinical pharmacology,...
- Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Varianton November 26, 2021 at 10:11 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern,...
- Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19on November 26, 2021 at 10:11 pm
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE) November 26, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482,...
- Starpharma releases positive DEP phase 2 interim results in prostate canceron November 26, 2021 at 8:11 pm
MELBOURNE, Australia, Nov. 26, 2021. Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP cabazitaxel. The company showed that 100% of evaluable patients...